Skip to content
Yog Pharma

Glimepiride is a sulfonylurea indicated for type 2 diabetes mellitus. We supply it to US manufacturers of tablets.

CAS93479-97-1490.6 g/molC24H34N4O5S
2D structure of Glimepiride.

Data from PubChem (CID 3476) and FDA’s substance registry

CAS number

93479-97-1

Molecular formula

C24H34N4O5S

Molecular weight

490.6g/mol

FDA UNII

IUPAC name

4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide

InChIKey

WIGIZIANZCJQQY-UHFFFAOYSA-N

Appearance
White to almost white powder.
Solubility
Practically insoluble in water, soluble in dimethylformamide and sparingly soluble in methylene chloride.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

A low-dose, poorly soluble API. Micronized material is typical, and content uniformity depends on a tight particle size distribution.

On the US market

Reference product
AmarylNDA 020496
Approved ANDAs
8 with a marketed product
Approved forms and strengths
  • Tablet 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, 8 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com